326 related articles for article (PubMed ID: 37511503)
1. Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting.
Radić J; Kožik B; Nikolić I; Kolarov-Bjelobrk I; Vasiljević T; Vranjković B; Despotović S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511503
[TBL] [Abstract][Full Text] [Related]
2. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
3. LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells.
Fan Z; Zheng W; Li H; Wu W; Liu X; Sun Z; Hu H; Du L; Jia Q; Liu Q
Oncol Rep; 2020 May; 43(5):1641-1649. PubMed ID: 32323822
[TBL] [Abstract][Full Text] [Related]
4. LOXL2 promotes vasculogenic mimicry and tumour aggressiveness in hepatocellular carcinoma.
Shao B; Zhao X; Liu T; Zhang Y; Sun R; Dong X; Liu F; Zhao N; Zhang D; Wu L; Wang Y; Wang M; Meng J; Lin X; Sun B
J Cell Mol Med; 2019 Feb; 23(2):1363-1374. PubMed ID: 30506621
[TBL] [Abstract][Full Text] [Related]
5. Significance of Lysyl oxidase‑like 2 gene expression on the epithelial‑mesenchymal status of hepatocellular carcinoma.
Ninomiya G; Yamada S; Hayashi M; Takeda S; Suenaga M; Takami H; Kanda M; Iwata N; Niwa Y; Tanaka C; Kobayashi D; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Oncol Rep; 2018 Jun; 39(6):2664-2672. PubMed ID: 29620290
[TBL] [Abstract][Full Text] [Related]
6. The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism.
Wu S; Xing X; Wang Y; Zhang X; Li M; Wang M; Wang Z; Chen J; Gao D; Zhao Y; Chen R; Ren Z; Zhang K; Cui J
Eur J Cancer; 2021 Apr; 147():63-73. PubMed ID: 33618200
[TBL] [Abstract][Full Text] [Related]
7. LOXL2 serves as a prognostic biomarker for hepatocellular carcinoma by mediating immune infiltration and vasculogenic mimicry.
Zhao N; Chen C; Guo Y; Liu T; Che N; Zhang D; Liang X; Zhang Y; Zhao X
Dig Liver Dis; 2023 May; 55(5):661-672. PubMed ID: 36192339
[TBL] [Abstract][Full Text] [Related]
8. LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer.
Zhu G; Wang L; Meng W; Lu S; Cao B; Liang X; He C; Hao Y; Du X; Wang X; Li L; Li L
Theranostics; 2021; 11(19):9198-9216. PubMed ID: 34646366
[TBL] [Abstract][Full Text] [Related]
9.
Yang YL; Tsai MC; Chang YH; Wang CC; Chu PY; Lin HY; Huang YH
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206143
[TBL] [Abstract][Full Text] [Related]
10. Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis.
Choi J; Chung T; Rhee H; Kim YJ; Jeon Y; Yoo JE; Noh S; Han DH; Park YN
Gut Liver; 2019 Jan; 13(1):83-92. PubMed ID: 29938458
[TBL] [Abstract][Full Text] [Related]
11. Matrix stiffness-mediated effects on macrophages polarization and their LOXL2 expression.
Xing X; Wang Y; Zhang X; Gao X; Li M; Wu S; Zhao Y; Chen J; Gao D; Chen R; Ren Z; Zhang K; Cui J
FEBS J; 2021 Jun; 288(11):3465-3477. PubMed ID: 32964626
[TBL] [Abstract][Full Text] [Related]
12. LOXL2 in cancer: regulation, downstream effectors and novel roles.
Wen B; Xu LY; Li EM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188435. PubMed ID: 32976981
[TBL] [Abstract][Full Text] [Related]
13. Matrix stiffness-upregulated LOXL2 promotes fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist pre-metastatic niche formation.
Wu S; Zheng Q; Xing X; Dong Y; Wang Y; You Y; Chen R; Hu C; Chen J; Gao D; Zhao Y; Wang Z; Xue T; Ren Z; Cui J
J Exp Clin Cancer Res; 2018 May; 37(1):99. PubMed ID: 29728125
[TBL] [Abstract][Full Text] [Related]
14. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.
Wong CC; Tse AP; Huang YP; Zhu YT; Chiu DK; Lai RK; Au SL; Kai AK; Lee JM; Wei LL; Tsang FH; Lo RC; Shi J; Zheng YP; Wong CM; Ng IO
Hepatology; 2014 Nov; 60(5):1645-58. PubMed ID: 25048396
[TBL] [Abstract][Full Text] [Related]
15. RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling.
Zhou YJ; Yang ML; He X; Gu HY; Ren JH; Cheng ST; Fu Z; Zhang ZZ; Chen J
J Exp Clin Cancer Res; 2024 Feb; 43(1):45. PubMed ID: 38326908
[TBL] [Abstract][Full Text] [Related]
16. The effect of LOXL2 in hepatocellular carcinoma.
Wu L; Zhang Y; Zhu Y; Cong Q; Xiang Y; Fu L
Mol Med Rep; 2016 Sep; 14(3):1923-32. PubMed ID: 27430160
[TBL] [Abstract][Full Text] [Related]
17. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.
Dinca SC; Greiner D; Weidenfeld K; Bond L; Barkan D; Jorcyk CL
Breast Cancer Res; 2021 May; 23(1):56. PubMed ID: 34011405
[TBL] [Abstract][Full Text] [Related]
18. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma.
Zheng N; Zhang S; Wu W; Zhang N; Wang J
Pharmacol Res; 2021 Apr; 166():105507. PubMed ID: 33610718
[TBL] [Abstract][Full Text] [Related]
19. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
[TBL] [Abstract][Full Text] [Related]
20. Frizzled 2-induced epithelial-mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinoma.
Ou H; Chen Z; Xiang L; Fang Y; Xu Y; Liu Q; Hu Z; Li X; Huang Y; Yang D
Cancer Sci; 2019 Apr; 110(4):1169-1182. PubMed ID: 30677195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
